The Generic Retribution
The generic industry has always been overshadowed by branded pharmaceuticals. The government policies and the mandate have also always favored branded pharmaceuticals. However, as the lawmakers come face to face with the rising drug costs and unmanageable healthcare expenditure, and in wake of growing public outcry, the government�s stance seems to softening. The generic industry�s appeals, which have been falling to deaf ears for so long, are finally being heard.
October sees a frenzy of biotech IPOs
October was the busiest month in three years for initial public offerings in the biotechnology sector. But the performance of the newly listed companies has been lacklustre as investors proved wary of betting on businesses that have yet to show a profit.
Venture Financing: Ready To Rebound?
There’s little doubt that the financing window has opened up, but investors, analysts and biotech companies themselves are still questioning just exactly how wide it will be and how long it will last.
Analyzing Brand-name and Generic Drug Costs in the U.S. and Eight Other Countries
A new Wharton study comparing average prices for pharmaceuticals in nine countries � the United States, Canada, Chile, France, Germany, Italy, Japan, Mexico and the United Kingdom � shows that average prices are highest in Japan, while prices in other countries are between 6% and 33% lower than prices in the U.S. Canada�s prices are the lowest.
Gene Tests? Not So Fast
The U.S. Food and Drug Administration Monday released draft guidelines regarding how genetic data could be used in new drug applications. Eventually, gene tests could predict exactly which patients might benefit from a particular drug. But this revolution will come slowly. The most telling words in the FDA’s guidance may be ‘draft–not for implementation.’
States flock to biotech like gamblers to lottery tickets
Florida lawmakers last month approved a $310 million biotech research center proposed by Gov. Jeb Bush just three months ago. New York launched a media campaign in September to woo more biotech investors. In the past two years, New Mexico, Kentucky and Arkansas started venture-capital funds to attract and nurture biotech start-ups.
Dozens of other states might be next. A recent Brookings Institution report notes that biotech ranked as the No. 1 or No. 2 target for 83% of 113 state and local economic agencies nationwide.